TCON
Price:
$0.0571
Market Cap:
$194.57K
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I...[Read more]
Industry
Biotechnology
IPO Date
2015-01-30
Stock Exchange
NASDAQ
Ticker
TCON
According to TRACON Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is 0.01. This represents a change of -98.76% compared to the average of 0.81 of the last 4 quarters.
The mean historical PE Ratio of TRACON Pharmaceuticals, Inc. over the last ten years is -3.72. The current 0.01 PE Ratio has changed -126.91% with respect to the historical average. Over the past ten years (40 quarters), TCON's PE Ratio was at its highest in in the September 2017 quarter at 11.33. The PE Ratio was at its lowest in in the June 2015 quarter at -11.73.
Average
-3.72
Median
-1.98
Minimum
-16.54
Maximum
-0.31
Discovering the peaks and valleys of TRACON Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 2.66%
Maximum Annual PE Ratio = -0.31
Minimum Annual Increase = -83.52%
Minimum Annual PE Ratio = -16.54
Year | PE Ratio | Change |
---|---|---|
2023 | -1.59 | 49.61% |
2022 | -1.06 | -36.08% |
2021 | -1.66 | -72.54% |
2020 | -6.06 | 1.83% |
2019 | -0.31 | -35.47% |
2018 | -0.49 | -83.52% |
2017 | -2.95 | 28.14% |
2016 | -2.30 | -45.33% |
2015 | -4.21 | -74.55% |
2014 | -16.54 | 2.66% |
The current PE Ratio of TRACON Pharmaceuticals, Inc. (TCON) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-1.44
5-year avg
-2.14
10-year avg
-3.72
TRACON Pharmaceuticals, Inc.’s PE Ratio is greater than Rezolute, Inc. (-3.80), greater than XOMA Corporation (-17.42), greater than Sio Gene Therapies Inc. (-4.77), greater than Vincerx Pharma, Inc. (-0.95), greater than Histogen Inc. (-0.10), greater than Entera Bio Ltd. (-7.78), greater than Tempest Therapeutics, Inc. (-0.88), greater than Better Therapeutics, Inc. (-0.00), greater than AN2 Therapeutics, Inc. (-0.47), greater than Miromatrix Medical Inc. (-3.41), greater than Inhibikase Therapeutics, Inc. (-0.55), greater than PMV Pharmaceuticals, Inc. (-1.58), greater than Anebulo Pharmaceuticals, Inc. (-4.99), greater than Candel Therapeutics, Inc. (-3.67), greater than Acurx Pharmaceuticals, Inc. (-1.87), greater than Monopar Therapeutics Inc. (-1.18), greater than Enochian Biosciences, Inc. (-1.24), greater than Kronos Bio, Inc. (-0.58), less than Cyclerion Therapeutics, Inc. (2.44), greater than Larimar Therapeutics, Inc. (-8.80), greater than Addex Therapeutics Ltd (-81.79), greater than Achilles Therapeutics plc (-0.45),
Company | PE Ratio | Market cap |
---|---|---|
-3.80 | $240.80M | |
-17.42 | $319.30M | |
-4.77 | $30.70M | |
-0.95 | $22.05M | |
-0.10 | $939.79K | |
-7.78 | $65.02M | |
-0.88 | $31.26M | |
-0.00 | $5.45K | |
-0.47 | $30.44M | |
-3.41 | $92.95M | |
-0.55 | $10.00M | |
-1.58 | $77.28M | |
-4.99 | $46.68M | |
-3.67 | $197.00M | |
-1.87 | $32.17M | |
-1.18 | $8.41M | |
-1.24 | $45.38M | |
-0.58 | $59.36M | |
2.44 | $7.94M | |
-8.80 | $513.64M | |
-81.79 | $17.80M | |
-0.45 | $29.58M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like TRACON Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like TRACON Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is TRACON Pharmaceuticals, Inc.'s PE Ratio?
How is the PE Ratio calculated for TRACON Pharmaceuticals, Inc. (TCON)?
What is the highest PE Ratio for TRACON Pharmaceuticals, Inc. (TCON)?
What is the 3-year average PE Ratio for TRACON Pharmaceuticals, Inc. (TCON)?
What is the 5-year average PE Ratio for TRACON Pharmaceuticals, Inc. (TCON)?
How does the current PE Ratio for TRACON Pharmaceuticals, Inc. (TCON) compare to its historical average?